Cerus Corp. (NASDAQ:CERS) shares saw unusually-high trading volume on Wednesday . Approximately 1,082,815 shares changed hands during trading, a decline of 3% from the previous session’s volume of 1,115,499 shares.The stock last traded at $6.48 and had previously closed at $6.30.

CERS has been the topic of a number of recent analyst reports. Robert W. Baird reaffirmed an “outperform” rating and set a $9.00 target price on shares of Cerus Corp. in a research report on Wednesday, June 22nd. BTIG Research reaffirmed a “buy” rating and set a $10.00 target price (up from $8.00) on shares of Cerus Corp. in a research report on Friday, April 22nd. FBR & Co reaffirmed a “buy” rating on shares of Cerus Corp. in a research report on Monday, July 11th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $9.00 target price on shares of Cerus Corp. in a research report on Thursday, July 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $8.90.

The firm’s 50-day moving average is $6.11 and its 200-day moving average is $5.81. The firm’s market cap is $669.25 million.

Cerus Corp. (NASDAQ:CERS) last released its earnings results on Tuesday, May 3rd. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.01. The company earned $7.60 million during the quarter, compared to analyst estimates of $8.29 million. The business’s revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.17) earnings per share. On average, equities research analysts predict that Cerus Corp. will post ($0.65) EPS for the current fiscal year.

Other hedge funds recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its stake in Cerus Corp. by 25.9% in the fourth quarter. Wells Fargo & Company MN now owns 4,901,666 shares of the company’s stock worth $30,979,000 after buying an additional 1,007,430 shares in the last quarter. EAM Investors LLC acquired a new position in Cerus Corp. during the fourth quarter worth approximately $1,139,000. Rail Splitter Capital Management LLC boosted its position in Cerus Corp. by 19.0% in the fourth quarter. Rail Splitter Capital Management LLC now owns 832,722 shares of the company’s stock worth $5,263,000 after buying an additional 132,970 shares during the last quarter. Stephens Inc. AR boosted its position in Cerus Corp. by 11.3% in the fourth quarter. Stephens Inc. AR now owns 1,112,665 shares of the company’s stock worth $7,032,000 after buying an additional 113,238 shares during the last quarter. Finally, California State Teachers Retirement System boosted its position in Cerus Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 176,709 shares of the company’s stock worth $1,117,000 after buying an additional 3,126 shares during the last quarter.

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.